Replies to post #224543 on Biotech Values

[DewDiligence]

ENTA—...Luly stated that similar to the HCV treatment, he expects that NASH and RSV treatments will be drug combinations.

Are you sure he didn't say NASH and HBV (rather than NASH and RSV)?

ENTA's RSV drug ought to work as a monotherapy.